Please login to the form below

Not currently logged in

AZ claims first-in-class win for Farxiga in heart failure

AZ in pursuit of class leader Jardiance


AstraZeneca has moved a step close to a chronic heart failure claim for its diabetes drug Farxiga after reporting positive results in a phase 3 trial.

The phase 3 DAPA-HF trial has shown that SGLT2 inhibitor Farxiga (dapagliflozin) was able to reduce cardiovascular death or the worsening of hearty failure, compared to placebo, in heart failure patients with reduced ejection fraction (HFrEF).

Farxiga was added to standard treatment in the study, and according to AZ is the first SGLT2 inhibitor to show a benefit in both diabetic and non-diabetic HFrEF patients.

Farxiga is already growing quickly for AZ on the back of new data showing it can reduce cardiovascular and kidney complications in diabetes patients, but a heart failure claim could add to its momentum by extending its use beyond diabetes.

Sales grew by a third to $1.4bn last year as Farxiga tries to chase down SGLT2 market leader Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim, which brought in around $2.7bn for the two partners in 2018 after becoming the first drug in the class to show an impact on cardiovascular outcomes.

At the same time, first-to-market SGLT2 inhibitor Invokana (canagliflozin) from Johnson & Johnson has been shrinking since the FDA added a label warning of lower-limb amputations risk in 2017.

Boehringer and Lilly have their own aspirations for a CHF label claim, and have just won a fast-track review from the FDA for Jardiance in both HFrEF and heart failure with preserved ejection fraction (HFpEF) based on two trials - EMPEROR-Reduced and EMPEROR-Preserved – that are due to read out next year.

The two partners also have another pair of trials under the EMPERIAL banner looking at exercise capacity and heart failure symptoms that are due to generate results before the end of this year.

Meanwhile, Farxiga is also being studied in HFpEF in the DELIVER trial as well as the DETERMINE study, which is enrolling both HFrEF and HFpEF patients. Those trials are also due to read out next year.

AZ has only revealed the top-line data from DAPA-HF, but for now seems to be in pole position for a heart failure claim for Farxiga in diabetic and non-diabetic HFrEF, and shares rose almost 2% this morning on the back of the announcement.

Mene Pangalos

Mene Pangalos

The company’s head of biopharma R&D, Mene Pangalos, said that at the moment “half of heart failure patients will die within five years of diagnosis and it remains one of the leading causes of hospitalisation.”

“We look forward to discussing the results of DAPA-HF with health authorities as soon as possible,” he added.

Article by
Phil Taylor

20th August 2019

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...